Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NPS Pharmaceuticals has extended its strategic alliance with AstraZeneca to discover, develop and market new drugs targeting metabotropic glutamate receptors for the treatment of various central nervous system and gastrointestinal disorders.
Subscribe to our email newsletter
Under the terms of the extended agreement, the companies will continue their research collaboration for a minimum of three years, with options to extend the alliance for an additional two years.
AstraZeneca is presently engaged in phase I clinical development activities with a metabotropic glutamate receptor (mGluR) active molecule discovered together with NPS.
“We are pleased to continue this collaboration with AstraZeneca, which has been very productive and has resulted in multiple lead product candidates for a variety of potential indications,” said Dr Hunter Jackson, chairman and CEO of NPS. “AstraZeneca’s continued desire to work with NPS reflects our shared enthusiasm for the prospects of generating multiple and important new products from this program.”